Cargando…
Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the cli...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072163/ https://www.ncbi.nlm.nih.gov/pubmed/37025355 http://dx.doi.org/10.1158/2767-9764.CRC-22-0438 |
_version_ | 1785019325733666816 |
---|---|
author | Sun, Boyang Qiu, Tian Zeng, Xiaoling Duan, Jianchun Bai, Hua Xu, Jiachen Li, Jin Li, Junling Hao, Xuezhi Liu, Yutao Lin, Lin Wang, Hongyu Zhang, Xin Zhong, Jia Wang, Jie Ying, Jianming Wang, Zhijie |
author_facet | Sun, Boyang Qiu, Tian Zeng, Xiaoling Duan, Jianchun Bai, Hua Xu, Jiachen Li, Jin Li, Junling Hao, Xuezhi Liu, Yutao Lin, Lin Wang, Hongyu Zhang, Xin Zhong, Jia Wang, Jie Ying, Jianming Wang, Zhijie |
author_sort | Sun, Boyang |
collection | PubMed |
description | Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the clinical relevance of MET polysomy. Cohort 1 included 53 patients whose tissues were available for both FISH and NGS assays. Paired plasma and tissue samples were obtained from 261 patients with NSCLC as cohort 2. Cohort 3 included 46 patients with metastatic NSCLC, who presented with MET copy-number gain assessed by NGS. ROC analysis demonstrated that a cut-off point of 2.3 copies achieved the maximum Youden index in discriminating polysomy from normal copy number. Compared with the FISH test for MET polysomy, the sensitivity, specificity, and agreement of NGS were 90%, 90%, and 96.2%, respectively. Following optimization using maximum somatic allele frequency, the sensitivity and specificity of NGS for defining polysomy using plasma samples according to different circulating tumor DNA mutation frequencies were 42% and 63%. The concordance rate between tissue and plasma samples for detecting polysomy was 85%. Regarding the response to MET inhibitor, the median progression-free survival (PFS) of the MET amplification group was significantly higher than that of the polysomy group. The median PFS was similar between the polysomy and normal groups. Our results indicated that NGS may serve as an alternative method for detecting MET polysomy in NSCLC tissues. Moreover, patients with MET polysomy may not benefit from MET inhibitors. SIGNIFICANCE: In this study, we established a methodology to differentiate polysomy from normal copy numbers and amplification using NGS. Moreover, this study suggests that it is critical to discriminate MET polysomy from amplification, for the former may dilute the clinical benefit of MET inhibitors. |
format | Online Article Text |
id | pubmed-10072163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-100721632023-04-05 Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors Sun, Boyang Qiu, Tian Zeng, Xiaoling Duan, Jianchun Bai, Hua Xu, Jiachen Li, Jin Li, Junling Hao, Xuezhi Liu, Yutao Lin, Lin Wang, Hongyu Zhang, Xin Zhong, Jia Wang, Jie Ying, Jianming Wang, Zhijie Cancer Res Commun Research Article Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the clinical relevance of MET polysomy. Cohort 1 included 53 patients whose tissues were available for both FISH and NGS assays. Paired plasma and tissue samples were obtained from 261 patients with NSCLC as cohort 2. Cohort 3 included 46 patients with metastatic NSCLC, who presented with MET copy-number gain assessed by NGS. ROC analysis demonstrated that a cut-off point of 2.3 copies achieved the maximum Youden index in discriminating polysomy from normal copy number. Compared with the FISH test for MET polysomy, the sensitivity, specificity, and agreement of NGS were 90%, 90%, and 96.2%, respectively. Following optimization using maximum somatic allele frequency, the sensitivity and specificity of NGS for defining polysomy using plasma samples according to different circulating tumor DNA mutation frequencies were 42% and 63%. The concordance rate between tissue and plasma samples for detecting polysomy was 85%. Regarding the response to MET inhibitor, the median progression-free survival (PFS) of the MET amplification group was significantly higher than that of the polysomy group. The median PFS was similar between the polysomy and normal groups. Our results indicated that NGS may serve as an alternative method for detecting MET polysomy in NSCLC tissues. Moreover, patients with MET polysomy may not benefit from MET inhibitors. SIGNIFICANCE: In this study, we established a methodology to differentiate polysomy from normal copy numbers and amplification using NGS. Moreover, this study suggests that it is critical to discriminate MET polysomy from amplification, for the former may dilute the clinical benefit of MET inhibitors. American Association for Cancer Research 2023-04-04 /pmc/articles/PMC10072163/ /pubmed/37025355 http://dx.doi.org/10.1158/2767-9764.CRC-22-0438 Text en © 2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. |
spellingShingle | Research Article Sun, Boyang Qiu, Tian Zeng, Xiaoling Duan, Jianchun Bai, Hua Xu, Jiachen Li, Jin Li, Junling Hao, Xuezhi Liu, Yutao Lin, Lin Wang, Hongyu Zhang, Xin Zhong, Jia Wang, Jie Ying, Jianming Wang, Zhijie Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors |
title | Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors |
title_full | Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors |
title_fullStr | Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors |
title_full_unstemmed | Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors |
title_short | Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors |
title_sort | detection of met polysomy by next-generation sequencing and its clinical relevance for met inhibitors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072163/ https://www.ncbi.nlm.nih.gov/pubmed/37025355 http://dx.doi.org/10.1158/2767-9764.CRC-22-0438 |
work_keys_str_mv | AT sunboyang detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT qiutian detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT zengxiaoling detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT duanjianchun detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT baihua detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT xujiachen detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT lijin detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT lijunling detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT haoxuezhi detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT liuyutao detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT linlin detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT wanghongyu detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT zhangxin detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT zhongjia detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT wangjie detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT yingjianming detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors AT wangzhijie detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors |